SI2528621T1 - Modificirani tuberkolozni antigeni - Google Patents

Modificirani tuberkolozni antigeni

Info

Publication number
SI2528621T1
SI2528621T1 SI201131036A SI201131036A SI2528621T1 SI 2528621 T1 SI2528621 T1 SI 2528621T1 SI 201131036 A SI201131036 A SI 201131036A SI 201131036 A SI201131036 A SI 201131036A SI 2528621 T1 SI2528621 T1 SI 2528621T1
Authority
SI
Slovenia
Prior art keywords
modified
tuberculosis antigens
tuberculosis
antigens
modified tuberculosis
Prior art date
Application number
SI201131036A
Other languages
English (en)
Slovenian (sl)
Inventor
Normand Blais
James Brown
Anne-Marie Gelinas
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.,
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A.,, Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.,
Publication of SI2528621T1 publication Critical patent/SI2528621T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI201131036A 2010-01-27 2011-01-27 Modificirani tuberkolozni antigeni SI2528621T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29871010P 2010-01-27 2010-01-27
PCT/EP2011/051158 WO2011092253A1 (en) 2010-01-27 2011-01-27 Modified tuberculosis antigens
EP11700859.9A EP2528621B1 (en) 2010-01-27 2011-01-27 Modified tuberculosis antigens

Publications (1)

Publication Number Publication Date
SI2528621T1 true SI2528621T1 (sl) 2017-01-31

Family

ID=44318698

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131036A SI2528621T1 (sl) 2010-01-27 2011-01-27 Modificirani tuberkolozni antigeni

Country Status (25)

Country Link
US (2) US8932600B2 (OSRAM)
EP (1) EP2528621B1 (OSRAM)
JP (2) JP6010463B2 (OSRAM)
KR (1) KR20120129927A (OSRAM)
CN (1) CN102869372B (OSRAM)
AU (1) AU2011209399B2 (OSRAM)
BR (1) BR112012018669A2 (OSRAM)
CA (1) CA2786969C (OSRAM)
CO (1) CO6650338A2 (OSRAM)
CY (1) CY1119518T1 (OSRAM)
DK (1) DK2528621T3 (OSRAM)
EA (1) EA201290590A1 (OSRAM)
ES (1) ES2614266T3 (OSRAM)
HR (1) HRP20161608T1 (OSRAM)
HU (1) HUE031184T2 (OSRAM)
LT (1) LT2528621T (OSRAM)
MX (1) MX2012008790A (OSRAM)
MY (1) MY156697A (OSRAM)
PH (1) PH12012501550A1 (OSRAM)
PL (1) PL2528621T3 (OSRAM)
PT (1) PT2528621T (OSRAM)
SG (1) SG182573A1 (OSRAM)
SI (1) SI2528621T1 (OSRAM)
UA (1) UA110103C2 (OSRAM)
WO (1) WO2011092253A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2315834T1 (sl) 2008-07-25 2018-09-28 Glaxosmithkline Biologicals S.A. Tuberkulozni Rv2386c protein, sestavki in njegove uporabe
DK2315773T3 (en) 2008-07-25 2016-12-12 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
NO2315597T3 (OSRAM) 2008-07-25 2018-01-20
WO2011092253A1 (en) * 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
EP4176897A1 (en) 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN105675863B (zh) * 2016-02-17 2017-10-20 遵义医学院附属医院 一组耐多药结核病诊断标志物及其用途
AU2017285424B2 (en) 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
CN109966170B (zh) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 包含生物大分子的柔性脂质体化妆品及其制备方法
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1786412A (en) * 1929-11-20 1930-12-23 American Telephone & Telegraph Shielding arrangement
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991012325A1 (en) * 1990-02-09 1991-08-22 E.I. Du Pont De Nemours And Company Htlv envelope antigenic segment
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU666326B2 (en) 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AT402926B (de) 1994-12-05 1997-09-25 Hafslund Nycomed Pharma Heterocyclische amide, verfahren zu ihrer herstellung und verwendung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9610262B1 (pt) 1995-09-01 2013-11-26 Compostos e métodos para a imunoterapia e diagnose de tuberculose.
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
PT2154248E (pt) 1995-09-01 2012-01-16 Corixa Corp Compostos e métodos para diagnóstico de tuberculose
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
TR199901569T2 (xx) 1996-10-11 2000-12-21 Corixa Corporation T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler.
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
KR100692227B1 (ko) 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
JP2003510370A (ja) * 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1542732B1 (en) 2000-06-20 2009-09-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7538206B2 (en) 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
CN101570594B (zh) 2002-02-14 2012-06-20 三井化学株式会社 聚酯树脂及聚酯制备用催化剂、用此催化剂制备聚酯树脂的方法
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
MXPA04012443A (es) * 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US7205259B2 (en) 2002-07-26 2007-04-17 Kimberly-Clark Worldwide, Inc. Absorbent binder desiccant composition and articles incorporating it
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
JP2008527947A (ja) 2005-01-19 2008-07-24 パンデュイット・コーポレーション 抑制コアを備えた通信チャンネル
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
EP1904848A2 (en) * 2005-04-29 2008-04-02 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
EP1880008B1 (en) 2005-05-03 2015-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression of mitochondrial protein by an enhanced allotopic approach
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
US20100183667A1 (en) 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
WO2008140478A2 (en) * 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
CL2008000611A1 (es) * 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
GB0716070D0 (en) * 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
FR2933552B1 (fr) 2008-07-04 2014-10-10 Centre Nat Rech Scient Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant
DK2315773T3 (en) * 2008-07-25 2016-12-12 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
US9074001B2 (en) 2009-04-24 2015-07-07 Statens Serum Institut Tuberculosis TB vaccine to prevent reactivation
WO2011011323A1 (en) 2009-07-21 2011-01-27 Cooper Technologies Company Interfacing a light emitting diode (led) module to a heat sink assembly, a light reflector and electrical circuits
WO2011092253A1 (en) * 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
EP2528621B1 (en) 2016-09-21
US20150093414A1 (en) 2015-04-02
CA2786969A1 (en) 2011-08-04
US9200044B2 (en) 2015-12-01
JP6503309B2 (ja) 2019-04-17
UA110103C2 (uk) 2015-11-25
CN102869372B (zh) 2016-01-20
US8932600B2 (en) 2015-01-13
KR20120129927A (ko) 2012-11-28
LT2528621T (lt) 2016-12-12
EP2528621A1 (en) 2012-12-05
CY1119518T1 (el) 2018-03-07
DK2528621T3 (da) 2017-01-02
ES2614266T3 (es) 2017-05-30
HRP20161608T1 (hr) 2017-01-13
HUE031184T2 (en) 2017-06-28
AU2011209399B2 (en) 2014-04-10
JP6010463B2 (ja) 2016-10-19
SG182573A1 (en) 2012-08-30
WO2011092253A1 (en) 2011-08-04
CN102869372A (zh) 2013-01-09
JP2013517783A (ja) 2013-05-20
AU2011209399A1 (en) 2012-08-23
PL2528621T3 (pl) 2017-07-31
EA201290590A1 (ru) 2013-03-29
JP2016166193A (ja) 2016-09-15
CO6650338A2 (es) 2013-04-15
PT2528621T (pt) 2016-12-20
BR112012018669A2 (pt) 2017-09-05
US20120294882A1 (en) 2012-11-22
MY156697A (en) 2016-03-15
CA2786969C (en) 2018-07-24
PH12012501550A1 (en) 2012-10-22
MX2012008790A (es) 2012-08-17

Similar Documents

Publication Publication Date Title
IL288203A (en) Meditops and Meditop binding antibodies and their use
LT2528621T (lt) Modifikuoti tuberkuliozės antigenai
IL259436A (en) Antibodies against 3angptl and their uses
IL232399A0 (en) Anti-2fgfr antibodies and their use
ZA201209004B (en) Anti-fgfr2 antibodies
PL2581113T3 (pl) Przeciwciało anty-tim-3
PT2530091T (pt) Anticorpo anti-dll3
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
IL225667A0 (en) A new antigen
PT2603528T (pt) Anticorpos glicosilados em fab
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies